[go: up one dir, main page]

GB1381426A - Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents - Google Patents

Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Info

Publication number
GB1381426A
GB1381426A GB1727573A GB1727573A GB1381426A GB 1381426 A GB1381426 A GB 1381426A GB 1727573 A GB1727573 A GB 1727573A GB 1727573 A GB1727573 A GB 1727573A GB 1381426 A GB1381426 A GB 1381426A
Authority
GB
United Kingdom
Prior art keywords
acid ester
polyoxyethylene
surface active
sulphuric acid
aliphatic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1727573A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to GB1727573A priority Critical patent/GB1381426A/en
Publication of GB1381426A publication Critical patent/GB1381426A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1381426 Pharmaceutical compositions CHUGAI SEIYAKU KK 10 April 1973 17275/73 Heading A5B Pharmaceutical compositions useful in the treatment of arteriosclerosis and having increased absorption of an oligosaccharide sulphuric acid ester through the wall of the digestive tract comprise at least one oligosaccharide sulphuric acid ester having an overage degree of polymerization of from 2 to 20, and at least one nonionic surface active agent in an amount of from 1 to 20% by weight based on the weight of the oligosaccharide sulphuric acid ester. The surface active agent may be a polyoxyethylene C 5-20 alcohol ether, a polyoxyethylene aliphatic acid ester, a sorbitan aliphatic acid ester, a polyoxyethylene sorbitan aliphatic acid ester, a polyoxyethylene sorbital aliphatic acid ester, a polyoxyethylene hydrogenated castor oil derivative, glyceryl monoaliphatic acid ester or a sucrose aliphatic acid ester. The compositions may be administered orally in the form of tablets, pills, granules, powders, capsules or aqueous preparations.
GB1727573A 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents Expired GB1381426A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1727573A GB1381426A (en) 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1727573A GB1381426A (en) 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Publications (1)

Publication Number Publication Date
GB1381426A true GB1381426A (en) 1975-01-22

Family

ID=10092354

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1727573A Expired GB1381426A (en) 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Country Status (1)

Country Link
GB (1) GB1381426A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056379A4 (en) * 1980-07-02 1983-10-07 Commw Scient Ind Res Org Controlled release compositions for administration of therapeutic agents to ruminants.
EP0147526A1 (en) * 1983-08-27 1985-07-10 BASF Aktiengesellschaft Method of enhancing the enteric resorption of heparin and a heparin preparation so obtained
EP0130550A3 (en) * 1983-06-29 1986-12-30 Intermedicat GmbH Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat
EP0230023A3 (en) * 1985-12-24 1988-11-17 Marion Laboratories Inc Pharmaceutical compositions for the enhancement of wound healing
EP0479093A1 (en) * 1990-10-03 1992-04-08 F. Hoffmann-La Roche Ag Oligosaccharide derivatives and their use as medicaments
EP1014996A4 (en) * 1997-08-28 2000-10-11 Univ Washington SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056379A4 (en) * 1980-07-02 1983-10-07 Commw Scient Ind Res Org Controlled release compositions for administration of therapeutic agents to ruminants.
EP0130550A3 (en) * 1983-06-29 1986-12-30 Intermedicat GmbH Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat
EP0147526A1 (en) * 1983-08-27 1985-07-10 BASF Aktiengesellschaft Method of enhancing the enteric resorption of heparin and a heparin preparation so obtained
US4656161A (en) * 1983-08-27 1987-04-07 Basf Aktiengesellschaft Increasing the enteral absorbability of heparin or heparinoids
EP0230023A3 (en) * 1985-12-24 1988-11-17 Marion Laboratories Inc Pharmaceutical compositions for the enhancement of wound healing
EP0479093A1 (en) * 1990-10-03 1992-04-08 F. Hoffmann-La Roche Ag Oligosaccharide derivatives and their use as medicaments
US5298616A (en) * 1990-10-03 1994-03-29 Hoffmann-La Roche Inc. Sulfated O-polysaccharide-trehaloses
EP1014996A4 (en) * 1997-08-28 2000-10-11 Univ Washington SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS

Similar Documents

Publication Publication Date Title
KR890009376A (en) Spray dried ibuprofen
ES424533A1 (en) Slow release pharmaceutical compositions
US5185159A (en) Pharmaceutical composition based on valproic acid and a process for preparing it
EP0165352A3 (en) Clear micellized solutions of fat soluble essential nutrients
DE3420283A1 (en) NIFEDIPINE DRY PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF
FR2698788B1 (en) Effervescent pharmaceutical composition containing ibuprofen and process for its preparation.
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
JPH10508287A (en) Method for stabilizing polyunsaturated fatty acids and use of the stabilized product for treatment and beauty
GB1381426A (en) Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents
SE8100104L (en) PHARMACEUTICAL COMPOSITIONS
IE821796L (en) Waterless thixotropic composition
KR940011014A (en) Stabilized Superoxide Dismutase (SOD) Compositions
ZA837412B (en) Compressed products with retarded release of active substance
US3777020A (en) Psoriasis treatment with mycophenolic acid
IE801402L (en) Gastric acid neutralizing agents
Windsor et al. Effect of tetracycline on leucocyte ascorbic acid levels
US4975423A (en) Inhibition of tumor development
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
KR880002266B1 (en) Tumor growth inhibiting composition
US4391809A (en) Methods for treating psoriasis
DE1543733C3 (en) Aluminum bis-alpha- (p-chlorophenoxy) isobutyrate and brightening agents containing this compound as an active ingredient
JPS5513241A (en) Remedy for glaucoma
DD249186A1 (en) METHOD OF MANUFACTURING A NEW GLIBENCLAMID MEDICAMENT WITH HIGHER BIODEGRADABILITY
DE2643303A1 (en) HYPOGLYKAEMICALLY ACTIVE DRUG
DE2050072C3 (en) Aluminum tri-3-acetyl-18 betaglycyrrthetinate, process for its preparation and pharmaceutical preparations containing it

Legal Events

Date Code Title Description
CSNS Application of which complete specification have been accepted and published, but patent is not sealed